MedTrace Logo

Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects.

NCT00847795 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2009-02-19

No results posted yet for this study

Summary

An exploratory Phase-II trial with intradermal RN1001 (Avotermin) to investigate scar prevention and reduction and acceleration of healing. The trial has an additional objective to evaluate several different scar assessment techniques that can be used in future clinical trials in the prevention and reduction of scarring.

Conditions

  • Cicatrix

Interventions

DRUG

Avotermin

Intradermal administration

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Renovo

    lead INDUSTRY

Principal Investigators

  • Jonathan Duncan, BS BCh · Renovo

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2003-06-30
Completion
2003-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00847795 on ClinicalTrials.gov